

Antibiotic Resistance – a growing problem in the US



NATIONAL ACTION PLAN FOR COMBATING ANTIBIOTIC-RESISTANT BACTERIA

MARCH 2015



Antimicrobial resistance threats- some you know and some you are going to see

WHO

Acinetobacter baumannii (carbapenem)

Pseudomonas aeruginosa (carbapenem)

Enterobacteriaceae, extended-spectrum- β -lactamase-producing (carbapenem)

Enterococcus faecium (vancomycin)

Staphylococcus aureus (methicillin, vancomycin)

Helicobacter pylori (clarithromycin)

Campylobacter spp. (fluoroquinolone)

Salmonellae (fluoroquinolone)

Neisseria gonorrhoeae (cephalosporin, fluoroquinolone)

CDC

Urgent Threats

- *Clostridium difficile*
- Carbapenem-resistant Enterobacteriaceae (CRE)
- Drug-resistant *Neisseria gonorrhoeae*

Serious Threats

- Multidrug-resistant *Acinetobacter*
- Drug-resistant *Campylobacter*
- Fluconazole-resistant *Candida* (a fungus)
- Extended spectrum β -lactamase producing Enterobacteriaceae (ESBLs)
- Vancomycin-resistant *Enterococcus* (VRE)
- Multidrug-resistant *Pseudomonas aeruginosa*
- Drug-resistant Non-typhoidal *Salmonella*
- Drug-resistant *Salmonella* Typhi
- Drug-resistant *Shigella*
- Methicillin-resistant *Staphylococcus aureus* (MRSA)
- Drug-resistant *Streptococcus pneumoniae*
- Drug-resistant tuberculosis

Concerning Threats

- Vancomycin-resistant *Staphylococcus aureus* (VRSA)
- Erythromycin-resistant Group A *Streptococcus*
- Clindamycin-resistant Group B *Streptococcus*

***Candida auris*- A multidrug resistant fungus**

- Emerging fungal pathogen that can be **resistant to multiple antifungal drugs (Azoles, Echinocandins and Amphotericin)**- overexpression of drug transporters
- CAN BE MISIDENTIFIED AS OTHER SPECIES (most often *C. haemulonii*)
- Invasive fatal infections reported (mostly in adults)
- Survives in environment and reported in outbreaks

**'Superbug' fungus new menace in US hospitals,
mostly NY, NJ**

<https://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-qanda.html>

What is antimicrobial stewardship?

- An activity that promotes:
 - ✓ The right antibiotic
 - ✓ At the right dose
 - ✓ By the right route and for the right duration
- Antimicrobial stewardship & appropriate antibiotic use have been shown to:
 - ✓ **Decrease *Clostridium difficile* infection**
 - ✓ Decrease resistance on patient and institution level
 - ✓ **Improve infection cure rates**
 - ✓ **Decrease antimicrobial costs**

- January 1, 2017: *new Joint Commission standards for hospital ASPs*
- Organizations will soon have to report antibiotic use data
- Providers should know:
 - ✓ What is antimicrobial stewardship and why it is important
 - ✓ What ASP resources are available at their hospital
 - ✓ ASP education needs to be provided for all patients being discharged on antibiotics

Antibiotic Stewardship is a Shared Responsibility: EVERYONE ACTS AS A STEWARD



A

Assess the patient

- Obtain history and perform physical exam
- Order the appropriate diagnostic studies
- Consider appropriate empiric antibiotics based on institutional guidelines and document the indication
- Clarify all antibiotic allergies in detail

C

Consider empiric therapy

- Re-evaluate and streamline antibiotics based on results of diagnostic studies (i.e., antibiotic time-out after 48-72 hours)
- Clearly define duration of therapy

T

Target therapy

**Prescribing principle:
Do not automatically assume IV
is better than oral.**

Know which drugs can be converted from IV to PO without loss of efficiency

Some antibiotics are equally effective IV vs. PO

Nurse-Driven Antibiotic Stewardship

Encourage the IV-to-PO Switch

Some antibiotics are just as effective when given IV or PO. If your patient can tolerate PO or enteral feeds and is improving clinically, feel empowered to prompt the IV-to-PO switch with the prescriber.

Did you know?
The prompt IV-to-PO switch results in multiple patient benefits e.g., decreased patient length of stay, costs of antibiotic, and days of IV therapy.

Azithromycin
Ciprofloxacin
Doxycycline
Levofloxacin
Linezolid
Metronidazole
Minocycline
Trimethoprim/Sulfamethoxazole
Voriconazole

Prescribing principle: Be aware of typical presentations and local resistance data

Do we need antibiotics for a drained abscess?

Should we cover for MRSA?

Important points

- Use purulence as a marker for *Staph aureus* infections
- You may not need antibiotics after a complete I&D
- For sensitive *Staphylococcus aureus* (MSSA) Vancomycin is **inferior** to beta lactams (Cefazolin/Oxacillin/Cephalexin)
- In the right setting if your prevalence of MRSA is low , one could possibly start with non-MRSA coverage (Cephalexin) for stable patients with non severe infections
- Bactrim and Clindamycin are often equivalent for MRSA.
- Doxycycline does not have a age restriction anymore

Risk factors for MRSA infection (a bit dated)

- *S. aureus* colonization
- Injection drug use
- Diabetes mellitus
- Chronic dermatologic conditions (e.g., eczema)
- Recent use of antimicrobial agents
- African-American race
- Previous SSTI
- Close contact with an SSTI patient
- Participation in contact sports
- Military personnel
- Prisoners

Standard dosing of drugs for MRSA infection

Drug	Dosing	Adverse Effects	Clinical pearl
Clindamycin	Adults: 450-600 mg IV/PO q6-8H Pediatrics: 10 mg/kg IV/PO q6-8H	Diarrhea, high risk of C-difficile infection	Can be used IN addition to a second drug for syndromes like toxic shock syndrome
Trimethoprim/ Sulfamethoxazole	SSTI: 8-10 mg/kg/day IV/PO divided q6-12H Pneumonia: 15-20 IV/PO mg/kg/day divided q6-12H	Renal toxicity (crystalluria), hyperkalemia, rash, Steven Johnsons (rare)	Traditionally considered sub-optimal for Group A strep
Doxycycline Minocycline	Adults: 100 mg IV/PO q12H Pediatrics: 2.2 mg/kg IV/PO q12H	Photosensitivity	There is no longer a age restriction! Watch out for DDIs with multivitamins

Vancomycin dosing pearls for pediatrics

- Trough is an **imperfect surrogate for efficacy** in pediatrics
- 15 mg/kg/dose every 6 hours for severe or invasive disease infections
- Consider a loading dose of 20 mg/kg/dose
- **Evidence of increasing renal toxicity with higher troughs and with combination therapy with Piperacillin/Tazobactam**
- Target troughs of 15-20 mcg/mL
 - Bacteremia
 - Infective endocarditis
 - Osteomyelitis
 - Meningitis
 - Pneumonia
 - Severe skin and soft tissue infections

Only target troughs of 10-15 mcg/mL for mild-moderate skin and soft tissue infections

Vancomycin dosing pearls for adults

- Usual starting dose: 15-20 mg/kg/dose
- Typical dosing interval is every 12 – 24 hours
 - Consider every 8 hour dosing if < 50 years old with severe infection and normal renal function
- A good rule of thumb – morbidly obese patients may require a lower mg/kg/day dose to achieve desired trough levels
- Total daily doses > 4 gm/day are at increase risk of nephrotoxicity

New drugs for MRSA infection

Drug	Dosing	Adverse Effects	Clinical pearl
Linezolid	<p>≥12 years: 600 mg IV/PO q12H</p> <p>1 month to < 12 years: 10 mg/kg/dose IV/PO q8H</p>	Thrombocytopenia (with prolonged courses), lactic acidosis, peripheral neuropathy	Watch out for DDIs with MAOIs, SSRIs (inc serotonin syndrome risk)
Ceftaroline	<p>Adults: 600 mg IV q8-12H</p> <p>Pediatrics: weight & age specific recommendations</p>	Hematologic abnormalities (seen with higher doses), rash	<p>Used in salvage MRSA bacteremia, endocarditis, pneumonia cases</p> <p>Brand only = \$\$\$</p> <p>Spectrum of activity: MRSA + ceftriaxone</p>
Daptomycin	6-8 mg/kg/dose q24H	Rhabdomyolysis (monitor CPK at least weekly), eosinophilic pneumonia	<p>Cannot be used for pneumonia (inactivated by lung surfactant)</p> <p>Higher doses typically required for <i>E. faecium</i> compared to MRSA</p>

New long acting drugs for MRSA infection

Drug	Adult Dosing (studied for SSTI)	Adverse Effects	Clinical pearl
Oritavancin	1200 mg x 1 single dose	Hypersensitivity reactions, infusion reactions, headache nausea	Exceptionally long half-life (~245 hrs), prolonged infusion (3 hrs), Brand only = \$\$\$
Dalbavancin	Single dose regimen: 1500 mg x 1 Two-dose regimen: 1000 mg x 1, 500 mg one week later	Hepatic effects, hypersensitivity, infusion reactions	Incredibly long half life (~350 hrs), Brand only = \$\$\$


Stewardship principles – Use diagnostic stewardship

My patient has pneumonia and is now **Coronavirus** positive?
Should I give antibiotics?

Diagnostic stewardship- what is it? Why does it matter?

- The art and science of using microbiologic tests to guide rational antibiotic use.
- Know how to interpret newly available microbiologic tests
- Know when NOT to treat a positive culture and how to distinguish false positives

Rapid molecular diagnostic methods are revolutionizing clinical microbiology laboratory but this increased sensitivity comes at a cost



The FilmArray BCID Panel
Simultaneous detection of 27 targets:

<p>Gram + Bacteria</p> <ul style="list-style-type: none"> Staphylococcus Staphylococcus aureus Streptococcus Streptococcus agalactiae 	<ul style="list-style-type: none"> Streptococcus pyogenes Streptococcus pneumoniae Enterococcus Listeria monocytogenes
<p>Gram - Bacteria</p> <ul style="list-style-type: none"> Klebsiella oxytoca Klebsiella pneumoniae Serratia Proteus Acinetobacter baumannii Haemophilus influenzae 	<ul style="list-style-type: none"> Neisseria meningitidis Pseudomonas aeruginosa Enterobacteriaceae Escherichia coli Enterobacter cloacae complex
<p>Fungi</p> <ul style="list-style-type: none"> Candida albicans Candida glabrata 	<ul style="list-style-type: none"> Candida krusei Candida parapsilosis Candida tropicalis
<p>Antibiotic Resistance</p> <ul style="list-style-type: none"> mecA vanA / vanB 	<ul style="list-style-type: none"> KPC

Enterobacter cloacae complex	
Method: Vitek Minimum Inhibitory Concentration	
Sensitivity	Value
Amikacin	<=2 S
Aztreonam	R
Cefepime	<=1 S
Cefoxitin	>=64 R
Ceftazidime	R
Ceftriaxone	R
Gentamicin	<=1 S
Levofloxacin	R
Meropenem	<=0.25S
Piperacillin-Tazobactam	>=128R
Tobramycin	<=1 S
Trimethoprim-Sulfamethoxazole	<=20 S

Now we have PCR assays available for rapid ID for multiple conditions- Respiratory infections

- Multiplex RT-PCR for respiratory viruses
- FilmArray Respiratory panel
- Viral: adenovirus; coronavirus (HKU1,NL63-229E,OC43); metapneumovirus, rhino/enterovirus; influenza (A,A/H1,A/H3, A/H1-2009,B); parainfluenza virus (type 1,2,3,4); respiratory syncytial virus
- Bacterial: *Bordetella pertussis*; *Chlamydomphila pneumoniae*; *Mycoplasma pneumoniae*



Rapid Blood Culture Pathogen Identification available at our hospital (so you might get results faster than before)

GRAM POSITIVES	GRAM NEGATIVES
<i>Enterococcus</i> , Vancomycin Susceptible	<i>Acinetobacter baumannii</i>
<i>Enterococcus</i> , Vancomycin Resistant	Enterics:
<i>Streptococcus pyogenes</i> (Group A)	<i>Enterobacter cloacae</i> complex
<i>Streptococcus agalactiae</i> (Group B)	<i>Escherichia coli</i>
<i>Streptococcus pneumoniae</i>	<i>Klebsiella oxytoca</i>
	<i>Klebsiella pneumoniae</i>
YEAST	<i>Proteus species</i>
<i>Candida albicans</i>	<i>Serratia marcescens</i>
<i>Candida glabrata</i>	KPC positive/negative
<i>Candida krusei</i>	<i>Haemophilus influenzae</i>
<i>Candida parapsilosis</i>	<i>Neisseria meningitidis</i>
<i>Candida tropicalis</i>	<i>Pseudomonas aeruginosa</i>

Remember that you do NOT have to treat every positive culture...

23-50% of antibiotic days for “UTI” may be unnecessary treatment for asymptomatic bacteriuria.

Whom to treat	Whom NOT to treat
<ul style="list-style-type: none">• Pregnant women• Patients undergoing urological procedures in which mucosal bleeding is anticipated	<ul style="list-style-type: none">• Diabetic patients• Patients with chronic indwelling urinary catheters• Patients who are immunocompromised• Patients about to undergo non-urologic surgery• Patients with urine cultures that grow MDR organisms



Stewardship principle – Think twice before labeling with an antibiotic allergy

I think my patient has a penicillin allergy and therefore should receive levofloxacin?

Remember : Being labeled with an antibiotic allergy is not trivial and has serious impact on patient outcomes

How should vague allergy histories be handled?

When any allergy with an unknown reaction is noted in a patient medical record every effort should be made to clarify the reaction ASAP

85-90% Percentage of reported beta-lactam allergies that **are not true allergies** → reduce antibiotic options **unnecessarily**.

Patients, their family members, and other care providers can often provide clarity

What do you need to ask?

- Date of reaction
- Timing (immediate vs. delayed)
- Treatment of reaction (epi/steroids)
- Has the patient tolerated other similar classes of medications
- Hives/angioedema/anaphylaxis (Type 1 reaction)
- Oral ulcers (Steven Johnsons syndrome)
- Joint pains (serum-sickness)
- Specific diagnosis given by provider : DRESS/ Acute Interstitial Nephritis/ Hemolytic Anemia

Evolving consensus on true PCN allergy

- PCN allergy is reported by approximately 10–20% of the population in the USA (higher in hospitalized patients)
- **Less than 10% of patients identifying as allergic have positive skin tests to penicillin**
- **90% of patients with labels are able to tolerate the medication without immediate-type hypersensitivity**

JAMA. 2001 May 16;285(19):2498-505.

Curr Allergy Asthma Rep (2017) 17: 40

CROSS REACTIVITY IS LOWER THAN YOU THINK

Cross-reactivity between penicillin and other beta-lactam classes (immediate-type hypersensitivity)

Beta Lactam Antibiotic	Cross Reactivity Rate
Monobactams (i.e., aztreonam)¹	0%
Cephalosporins²	3-4%
Carbapenems (e.g. Meropenem)	<1%

¹ Avoid aztreonam if the patient has had a previous reaction to ceftazidime

² Patients with previous reaction to amoxicillin or ampicillin should avoid cephalosporins with identical R group side chains:

Amoxicillin: cefadroxil, cefprozil

Ampicillin: cefaclor, cephalexin

Cross reactivity charts– Beta-lactams and Cephalosporins (available online)

	Penicillin G	Amoxicillin	Ampicillin	Cephalexin	Cefadroxil	Cefaclor	Cefotetan	Cefoxitin	Cefprozil	Cefuroxime	Cefdinir	Cefixime	Cefotaxime	Cefpodoxime	Ceftazidime	Ceftriaxone	Cefepime
Penicillin G	■							X									
Amoxicillin		■	X	X	X	X			X								
Ampicillin		X	■	X	X	X			X								
Cephalexin		X	X	■	X	X			X								
Cefadroxil		X	X	X	■	X			X								
Cefaclor		X	X	X	X	■			X								
Cefotetan							■										
Cefoxitin	X							■		X							
Cefprozil		X	X	X	X	X			■								
Cefuroxime								X		■							
Cefdinir											■	X					
Cefixime											X	■					
Cefotaxime													■	X		X	X
Cefpodoxime													X	■		X	X
Ceftazidime															■		
Ceftriaxone													X	X		■	X
Cefepime													X	X		X	■

X indicates a similar side chain and therefore potential for cross-reactivity

Prescribing principle: You can probably go shorter in terms of antibiotic duration

The New Mantra: Shorter is Better!

Table. Infections for Which Short-Course Therapy Has Been Shown to Be Equivalent in Efficacy to Longer Therapy

Disease	Treatment, Days	
	Short	Long
Community-acquired pneumonia ¹⁻³	3-5	7-10
Nosocomial pneumonia ^{6,7}	≤8	10-15
Pyelonephritis ¹⁰	5-7	10-14
Intraabdominal infection ¹¹	4	10
Acute exacerbation of chronic bronchitis and COPD ¹²	≤5	≥7
Acute bacterial sinusitis ¹³	5	10
Cellulitis ¹⁴	5-6	10
Chronic osteomyelitis ¹⁵	42	84

Abbreviation: COPD, chronic obstructive pulmonary disease.

Prescribing principles – summary

- Do not automatically assume IV is better than PO.
- Know your local epidemiology and susceptibilities.
- Practice diagnostic stewardship
- Think twice before labeling with an antibiotic allergy
- You can probably do a shorter duration than you think